IKT vs. NSTGQ, SRNE, ONVO, PALI, CELZ, TTNP, BCDA, GENE, CHRO, and FRTX
Should you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include NanoString Technologies (NSTGQ), Sorrento Therapeutics (SRNE), Organovo (ONVO), Palisade Bio (PALI), Creative Medical Technology (CELZ), Titan Pharmaceuticals (TTNP), BioCardia (BCDA), Genetic Technologies (GENE), Chromocell Therapeutics (CHRO), and Fresh Tracks Therapeutics (FRTX). These companies are all part of the "biological products, except diagnostic" industry.
NanoString Technologies (NASDAQ:NSTGQ) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, community ranking, profitability, valuation and risk.
Inhibikase Therapeutics has lower revenue, but higher earnings than NanoString Technologies. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than NanoString Technologies, indicating that it is currently the more affordable of the two stocks.
NanoString Technologies has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.
In the previous week, Inhibikase Therapeutics had 6 more articles in the media than NanoString Technologies. MarketBeat recorded 6 mentions for Inhibikase Therapeutics and 0 mentions for NanoString Technologies. NanoString Technologies' average media sentiment score of 0.38 beat Inhibikase Therapeutics' score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.
Inhibikase Therapeutics has a consensus price target of $27.00, indicating a potential upside of 1,460.69%. Given NanoString Technologies' higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than NanoString Technologies.
NanoString Technologies has a net margin of -102.44% compared to NanoString Technologies' net margin of -5,886.15%. Inhibikase Therapeutics' return on equity of 0.00% beat NanoString Technologies' return on equity.
Inhibikase Therapeutics received 5 more outperform votes than NanoString Technologies when rated by MarketBeat users.
76.8% of NanoString Technologies shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 3.1% of NanoString Technologies shares are owned by insiders. Comparatively, 20.3% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Inhibikase Therapeutics beats NanoString Technologies on 10 of the 16 factors compared between the two stocks.
Get Inhibikase Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inhibikase Therapeutics Competitors List
Related Companies and Tools
